Signaling lymphocyte activation molecule family in systemic lupus erythematosus.
Journal
Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
11
07
2018
revised:
04
11
2018
accepted:
05
11
2018
pubmed:
12
11
2018
medline:
31
3
2020
entrez:
12
11
2018
Statut:
ppublish
Résumé
Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease characterized by a breakdown in immune tolerance leading to the development of auto-reactive lymphocytes and autoantibodies. Recent findings have provided new insight on the role of the signaling lymphocytic activation molecule family (SLAMF) receptors, a group of nine co-regulatory molecules involved in the activation of hematopoietic cells, and their downstream protein SLAM-associated protein (SAP), into the pathogenesis of SLE. This review summarizes the current knowledge on SLAMF in human SLE immunopathogenesis, and the importance of SLAMF molecules as new therapeutic targets.
Identifiants
pubmed: 30415085
pii: S1521-6616(18)30442-X
doi: 10.1016/j.clim.2018.11.001
pii:
doi:
Substances chimiques
Signaling Lymphocytic Activation Molecule Family
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
57-63Subventions
Organisme : NIAID NIH HHS
ID : P01 AI065687
Pays : United States
Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.